(Q37790601)

23 August 2017

PMDA's challenge to accelerate clinical development and review of new drugs in Japan (English)

1 reference

23 August 2017

1 reference

K Ichimaru

1

1 reference

23 August 2017

S Toyoshima

series ordinal

2

1 reference

23 August 2017

Y Uyama

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Clinical Pharmacology & Therapeutics

23 August 2017

1 reference

23 August 2017

88

1 reference

23 August 2017

4

1 reference

23 August 2017

454-457

1 reference

Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.190

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.190

Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.190

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.190

Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.190

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.190

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.190

1 reference

23 August 2017

1 reference